Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ellagic acid to preparation of medicine for preventing and treating multiple sclerosis

A technology for multiple sclerosis and ellagic acid, which is applied in the fields of biomedicine and pharmaceutical applications, and can solve the problems of limited drugs and no reported effects in the literature.

Inactive Publication Date: 2019-03-08
SHAANXI NORMAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are limited drugs for the treatment of MS. It is very important for a more effective treatment of MS to find a new drug that can specifically inhibit the migration of peripheral inflammatory cells to the central nervous system, and the drug itself has no toxic side effects on the body.
However, there is no literature reporting the role of EA in autoimmune diseases, especially in multiple sclerosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ellagic acid to preparation of medicine for preventing and treating multiple sclerosis
  • Application of ellagic acid to preparation of medicine for preventing and treating multiple sclerosis
  • Application of ellagic acid to preparation of medicine for preventing and treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Different doses of ellagic acid used to improve acute-experimental autoimmune encephalomyelitis

[0023] 1. Experimental treatment

[0024] (1) Establish EAE model

[0025] Eight-week-old female C57BL / 6J mice were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. Myelin oligodendrocyte glycoprotein peptide (MOG 35-55 ), purchased from Genescript Company, pertussis toxin, purchased from Sigma-Aldrich Company, complete Freund's adjuvant containing Mycobacterium tuberculosis, purchased from BD Difco Company.

[0026] 200 μL containing 200 μg myelin oligodendrocyte glycoprotein peptide (MOG 35-55 ), 50% volume of complete Freund's adjuvant and 5 mg / mL Mycobacterium tuberculosis H37Ra (Sigma-Aldrich) mixed into an emulsion and subcutaneously immunized mice at two sites on the back. Pertussis toxin dilution (200ng / cause) was injected intraperitoneally on the day of immunization and 2 days later.

[0027] Grouping and dosing:

[0028] ①PBS control group: PBS was a...

Embodiment 2

[0035] Different doses of intraperitoneal injection and different treatment stages of ellagic acid for the improvement of acute-experimental autoimmune encephalomyelitis experiment

[0036] 1. Experimental treatment

[0037] The EAE model was established according to the method of Example 1.

[0038] Grouping and dosing:

[0039] ①PBS control group: Intraperitoneal injection was performed every day from the day of immunization.

[0040] ②Ellagic acid treatment group: On the day of immunization, different doses of ellagic acid (10 mg / kg, 5 mg / kg, 1 mg / kg, 0.5 mg / kg) were injected into the intraperitoneal cavity every day, and in the early stage and high incidence stage of the disease, respectively, every day Ellagic acid (5 mg / kg) was administered by intraperitoneal injection.

[0041] 2. Post-experiment processing

[0042] (1) EAE clinical score: the same scoring standard as in Example 1, the clinical score was performed on the onset of the mice every day, and the neurolog...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ellagic acid to preparation of a medicine for preventing and treating multiple sclerosis. An experimental autoimmune encephalomyelitis whole animal model experiment proves that the occurrence and development of experimental autoimmune encephalomyelitis can be effectively prevented through oral administration or intraperitoneal injection of the ellagic acid; the infiltration of peripheral inflammatory cells to a central nervous system is remarkably inhibited and the demyelination degree is alleviated; the ellagic acid also has a very good treatment effecton model animals at an initial period and fastigium of incidence. Therefore, the ellagic acid has a great potential for preparing the medicine for preventing and treating the multiple sclerosis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and drug application, and specifically relates to the application of ellagic acid in the preparation of drugs for preventing and treating multiple sclerosis. Background technique [0002] Multiple sclerosis (Multiple Sclerosis, MS) is a disease of the central nervous system (Central Nervous System, CNS), which is a diverse, multifactorial, immune system-mediated disease that is influenced by genetic and environmental factors Affects, characterized by demyelination and inflammatory infiltrates. Experimental Autoimmune Encephalomyelitis (EAE) is an ideal animal model. About 2.5 million people worldwide suffer from this disease, and the incidence rate continues to increase. [0003] The pathogenesis of MS has not yet been fully elucidated. Among them, the abnormal immune response of the body often first leads to an increase in the number of peripheral inflammatory cells, thereby destroying the b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/366A61P25/00A61P37/02
CPCA61K31/366A61P25/00A61P37/02
Inventor 张媛申沛鑫李星鹿欣雨赵莉
Owner SHAANXI NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com